title: In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenic.
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Boston, MA.
authors.forename: E L
authors.initials: EL
authors.lastname: Ramos
authors.forename: J E
authors.initials: JE
authors.lastname: Leggat
authors.forename: E L
authors.initials: EL
authors.lastname: Milford
authors.forename: R L
authors.initials: RL
authors.lastname: Kirkman
authors.forename: N L
authors.initials: NL
authors.lastname: Tilney
authors.forename: T B
authors.initials: TB
authors.lastname: Strom
authors.forename: M E
authors.initials: ME
authors.lastname: Shapiro
authors.forename: T A
authors.initials: TA
authors.lastname: Waldmann
authors.forename: C B
authors.initials: CB
authors.lastname: Carpenter
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic; D006084:Graft Rejection; D006801:Humans; D007108:Immune Tolerance; D007165:Immunosuppression Therapy; D066298:In Vitro Techniques; D016030:Kidney Transplantation / Q000276:immunology*; D007959:Lymphocyte Culture Test, Mixed; D016032:Randomized Controlled Trials as Topic; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2